The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status – a Danish nation-wide cohort study

Rotbain EC, Rostgaard K, Kaastrup K, Mikkelsen SU, Hjalgrim H, Grønbæk K. The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status – a Danish nation-wide cohort study. Acta Oncol. 2025;64:623–9.

https://doi.org/10.2340/1651-226X.2025.42422 DOI: https://doi.org/10.2340/1651-226X.2025.42422

Alfian SD, Sukandar H, Lestari K, Abdulah R, Diantini A. Medication adherence in patients with type 2 diabetes: a systematic review. Diabetes Res Clin Pract. 2022;186:110239.

https://doi.org/10.1016/j.diabres.2022.110239

Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9(5):293-303. https://doi.org/10.1016/S2213-8587(21)00050-4 DOI: https://doi.org/10.1016/S2213-8587(21)00050-4

Wang Y, Zhao Y, Li X, Chen Z, Liu H, Zhang T, et al. Obesity and risk of myelodysplastic syndromes and acute myeloid leukemia: a meta-analysis. Br J Cancer. 2022;126(3):530–8.

https://doi.org/10.1038/s41416-022-01722-2

Kwok B, Hall JM, Witte ON, Levine RL, Jaiswal S, Ebert BL, et al. Inflammation and clonal hematopoiesis: a double-edged sword in hematologic malignancies. Blood Adv. 2020;4(11):2568–2577.

https://doi.org/10.1182/bloodadvances.2019000993